Compare DexCom, Inc. (DXCM) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while JPMorgan Equity Premium Income ETF trades at $57.88. The key difference: DexCom, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | JEPI | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $59.88 |
52-Week Low | $54.84 | $55.29 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
JEPI trades at $57.84, up 0.35% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent dividends of $0.39 and $0.37 highlight its income focus, while news coverage emphasizes its role in retirement portfolios amid competitive yield pressures from peers like SPYI and JEPQ.
The outlook is mixed: strong income appeal supports demand, but underperformance versus covered-call peers and tax inefficiencies risk long-term returns. Investors face trade-offs between monthly distributions and capital appreciation, with sentiment divided on whether JEPI's strategy justifies opportunity costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
